Edgewise Therapeutics, Inc.
EWTX
$13.45
$0.423.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.43% | 44.90% | 28.49% | 21.12% | 13.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.49% | 37.28% | 50.39% | 35.20% | 53.37% |
| Operating Income | -34.49% | -37.28% | -50.39% | -35.20% | -53.37% |
| Income Before Tax | -31.58% | -32.73% | -46.71% | -24.90% | -55.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.58% | -32.73% | -46.71% | -24.90% | -55.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.58% | -32.73% | -46.71% | -24.90% | -55.26% |
| EBIT | -34.49% | -37.28% | -50.39% | -35.20% | -53.37% |
| EBITDA | -34.70% | -37.55% | -51.02% | -34.38% | -51.78% |
| EPS Basic | 10.03% | 10.22% | 0.56% | 9.78% | -51.60% |
| Normalized Basic EPS | 10.01% | 10.19% | 0.57% | 9.75% | -51.54% |
| EPS Diluted | 10.03% | 10.22% | 0.56% | 8.59% | -51.60% |
| Normalized Diluted EPS | 10.01% | 10.19% | 0.57% | 9.75% | -51.54% |
| Average Basic Shares Outstanding | 46.23% | 47.83% | 47.55% | 38.41% | 2.44% |
| Average Diluted Shares Outstanding | 46.23% | 47.83% | 47.55% | 38.41% | 2.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |